Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Venomous snail provides Eisai with new painkiller

July 7, 2006 Research and Development, Sales and Marketing

Patients suffering severe chronic pain have new hope of relief thanks to a venomous sea snail found off the coast …
News

Gene therapy: the tailor-made treatment

June 28, 2006 Research and Development drug development, gene therapy

 At the risk of boring my audience, I really can't help beginning with yet another attack of nostalgia ,or rather …
Feature

Novartis buys Manchester-based biotech and superbug drugs

June 21, 2006 Research and Development

UK biotech NeuTec is to be acquired by Swiss pharma giant Novartis which says the company's two anti-infective drug candidates …
News

Cancer vaccine continues to show encouraging results

June 14, 2006 Research and Development

Oxford BioMedica, the UK gene therapy specialist, has reported encouraging results from five phase II studies of TroVax, its leading …
News

Blockbuster potential for diabetes vision drug

June 13, 2006 Research and Development, Sales and Marketing

Lilly says new phase III data on its drug Arxxant shows it can stop diabetes patients losing their sight.Data from …
News

Phytopharm looks for licensing partner for Alzheimer drug

May 24, 2006 Research and Development

Specialist pharma company Phytopharm says it is confident of finding a partner to develop and market one of its lead …
News

Exelon is first drug for Parkinson’s disease dementia

May 24, 2006 Research and Development

Exelon has been launched as the first ever treatment for mild to moderately severe dementia associated with idiopathic Parkinson's disease.The …
News

Industry experts to advise Northwick Park investigation

May 19, 2006 Research and Development

Experts from the UK's pharmaceutical and biotech industries are to assist the inquiry into the Northwick Park drug trial, which …
News

AstraZeneca’s

May 18, 2006 Research and Development, Sales and Marketing

AstraZeneca is to buy Cambridge Antibody Technology for 702 million pounds in a bid to expand its reach into biotechnology.Cambridge …
News

Kendle spends $215 million to become major clinical research player

May 12, 2006 Research and Development

Kendle is to spend $215 million on buying the business of rivals Charles River, a move which the companys leaders …
News

Merck buys antibody design specialists

May 10, 2006 Research and Development

Merck is to buy a pioneering biotech company, which discovers new monoclonal antibodies and then re-engineers them to make them …
News

AstraZeneca abandons diabetes drug over safety concerns

May 5, 2006 Research and Development AstraZeneca, PPAR agonist

 AstraZeneca is to abandon its late-stage diabetes drug Galida after new results raised doubts about its safety.Galida is a PPAR …
News

Project management: from apprentice to master

May 3, 2006 Research and Development, Sales and Marketing

When the three 'Apprentices' enter Mr. Sugars boardroom to explain why they made such a hash of their latest project, …
Feature

Positive results halt trial of new Herceptin rival

May 3, 2006 Research and Development

Better than expected results for a new drug for advanced breast cancer have led to trials being halted, in order …
News

Biotech buy helps Pfizer expand neuroscience research

April 26, 2006 Research and Development, Sales and Marketing Pfizer

Pfizer is to buy Californian Rinat Neuroscience, a biotech company which specialises in developing therapeutic proteins to treat central nervous …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026